🇪🇺 Pulverized ticagrelor orally in European Union

EMA authorised Pulverized ticagrelor orally on 3 December 2010

Marketing authorisation

EMA — authorised 3 December 2010

  • Application: EMEA/H/C/001241
  • Marketing authorisation holder: AstraZeneca AB
  • Local brand name: Brilique
  • Indication: Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event Brilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.
  • Status: approved

Read official source →

Pulverized ticagrelor orally in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Pulverized ticagrelor orally approved in European Union?

Yes. EMA authorised it on 3 December 2010.

Who is the marketing authorisation holder for Pulverized ticagrelor orally in European Union?

AstraZeneca AB holds the EU marketing authorisation.